Archives

by in
Entry Author Date Location
Relypsa Aims to Delay Need for Costly Dialysis in Kidney Patients 02/05/14 San Francisco
Fresh from IPO, Five Prime Advances Arthritis and Cancer Drugs 12/19/13 San Francisco
5AM Ventures, an Early Stage Biotech VC Still Standing, Raises $250M 12/04/13 San Francisco
ZS Pharma Passes Key Test With Drug for Hyperkalemia 11/20/13 Texas
As Total U.S. IPOs Mount, Several Biotech Deals Stumble 11/19/13 San Diego
Relypsa Secures $75,900,000 New Financing Round 11/15/13 San Francisco
Relypsa Receives $2,587,888 New Funding Round 12/11/12 San Francisco
Relypsa Obtains $12,734,652 New Financing 10/08/12 San Francisco
Relypsa Gets Another $50M for Drug to Fight Excess Potassium 08/13/12 San Francisco
Relypsa Obtains $49,677,652 New Financing Round 08/13/12 San Francisco
Sorbent Therapeutics Seeks to Fight Heart Failure in Unusual Arena: The Gut 07/13/11 San Francisco
Sorbent Therapeutics Absorbs $36M to Go After New Treatment For Kidney, Heart Failure 06/30/11 San Francisco
Nodality’s Personalized Medicine Recipe, Relypsa Pockets $70M, Big Oil Likes Seaweed Biofuel, & More Bay Area Life Sciences News 09/17/10 San Francisco
Relypsa Snags $70M Venture Round to Get Rid of Excess Potassium in Blood 09/13/10 San Francisco
Relypsa Obtains $70,000,000 Series B Funding 09/13/10 San Francisco
Relypsa Lands $10,000,000 Series A Financing Round 03/11/09 San Francisco
Page 1 of 1